IBDEI1E0 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24586,2)
 ;;=^89209
 ;;^UTILITY(U,$J,358.3,24587,0)
 ;;=V08.^^140^1513^24
 ;;^UTILITY(U,$J,358.3,24587,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24587,1,2,0)
 ;;=2^V08.
 ;;^UTILITY(U,$J,358.3,24587,1,5,0)
 ;;=5^HIV,ASYMPTOMATIC
 ;;^UTILITY(U,$J,358.3,24587,2)
 ;;=^303392
 ;;^UTILITY(U,$J,358.3,24588,0)
 ;;=603.9^^140^1513^26
 ;;^UTILITY(U,$J,358.3,24588,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24588,1,2,0)
 ;;=2^603.9
 ;;^UTILITY(U,$J,358.3,24588,1,5,0)
 ;;=5^HYDROCELE NOS
 ;;^UTILITY(U,$J,358.3,24588,2)
 ;;=^59548
 ;;^UTILITY(U,$J,358.3,24589,0)
 ;;=272.0^^140^1513^27
 ;;^UTILITY(U,$J,358.3,24589,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24589,1,2,0)
 ;;=2^272.0
 ;;^UTILITY(U,$J,358.3,24589,1,5,0)
 ;;=5^HYPERCHOLESTEROLEM
 ;;^UTILITY(U,$J,358.3,24589,2)
 ;;=^59973
 ;;^UTILITY(U,$J,358.3,24590,0)
 ;;=272.4^^140^1513^28
 ;;^UTILITY(U,$J,358.3,24590,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24590,1,2,0)
 ;;=2^272.4
 ;;^UTILITY(U,$J,358.3,24590,1,5,0)
 ;;=5^HYPERLIPIDEMIA NEC/NOS
 ;;^UTILITY(U,$J,358.3,24590,2)
 ;;=^87281
 ;;^UTILITY(U,$J,358.3,24591,0)
 ;;=276.7^^140^1513^29
 ;;^UTILITY(U,$J,358.3,24591,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24591,1,2,0)
 ;;=2^276.7
 ;;^UTILITY(U,$J,358.3,24591,1,5,0)
 ;;=5^HYPERPOTASSEMIA
 ;;^UTILITY(U,$J,358.3,24591,2)
 ;;=^60042
 ;;^UTILITY(U,$J,358.3,24592,0)
 ;;=401.9^^140^1513^30
 ;;^UTILITY(U,$J,358.3,24592,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24592,1,2,0)
 ;;=2^401.9
 ;;^UTILITY(U,$J,358.3,24592,1,5,0)
 ;;=5^HYPERTENSION NOS
 ;;^UTILITY(U,$J,358.3,24592,2)
 ;;=^186630
 ;;^UTILITY(U,$J,358.3,24593,0)
 ;;=401.1^^140^1513^31
 ;;^UTILITY(U,$J,358.3,24593,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24593,1,2,0)
 ;;=2^401.1
 ;;^UTILITY(U,$J,358.3,24593,1,5,0)
 ;;=5^HYPERTENSION,BENIGN
 ;;^UTILITY(U,$J,358.3,24593,2)
 ;;=^269591
 ;;^UTILITY(U,$J,358.3,24594,0)
 ;;=401.0^^140^1513^32
 ;;^UTILITY(U,$J,358.3,24594,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24594,1,2,0)
 ;;=2^401.0
 ;;^UTILITY(U,$J,358.3,24594,1,5,0)
 ;;=5^HYPERTENSION,MALIGNANT
 ;;^UTILITY(U,$J,358.3,24594,2)
 ;;=^73505
 ;;^UTILITY(U,$J,358.3,24595,0)
 ;;=242.90^^140^1513^33
 ;;^UTILITY(U,$J,358.3,24595,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24595,1,2,0)
 ;;=2^242.90
 ;;^UTILITY(U,$J,358.3,24595,1,5,0)
 ;;=5^HYPERTHYROIDISM
 ;;^UTILITY(U,$J,358.3,24595,2)
 ;;=^267811
 ;;^UTILITY(U,$J,358.3,24596,0)
 ;;=272.1^^140^1513^34
 ;;^UTILITY(U,$J,358.3,24596,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24596,1,2,0)
 ;;=2^272.1
 ;;^UTILITY(U,$J,358.3,24596,1,5,0)
 ;;=5^HYPERTRIGLYCERIDEMIA
 ;;^UTILITY(U,$J,358.3,24596,2)
 ;;=^101303
 ;;^UTILITY(U,$J,358.3,24597,0)
 ;;=251.2^^140^1513^35
 ;;^UTILITY(U,$J,358.3,24597,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24597,1,2,0)
 ;;=2^251.2
 ;;^UTILITY(U,$J,358.3,24597,1,5,0)
 ;;=5^HYPOGLYCEMIA NOS
 ;;^UTILITY(U,$J,358.3,24597,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,24598,0)
 ;;=276.1^^140^1513^36
 ;;^UTILITY(U,$J,358.3,24598,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24598,1,2,0)
 ;;=2^276.1
 ;;^UTILITY(U,$J,358.3,24598,1,5,0)
 ;;=5^HYPONATREMIA
 ;;^UTILITY(U,$J,358.3,24598,2)
 ;;=^60722
 ;;^UTILITY(U,$J,358.3,24599,0)
 ;;=276.8^^140^1513^37
 ;;^UTILITY(U,$J,358.3,24599,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24599,1,2,0)
 ;;=2^276.8
 ;;^UTILITY(U,$J,358.3,24599,1,5,0)
 ;;=5^HYPOPOTASSEMIA
 ;;^UTILITY(U,$J,358.3,24599,2)
 ;;=^60611
 ;;^UTILITY(U,$J,358.3,24600,0)
 ;;=458.9^^140^1513^38
 ;;^UTILITY(U,$J,358.3,24600,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24600,1,2,0)
 ;;=2^458.9
 ;;^UTILITY(U,$J,358.3,24600,1,5,0)
 ;;=5^HYPOTENSION NOS
 ;;
 ;;$END ROU IBDEI1E0
